Evidence map›Paper›PMID 34681659›Full record

ArticleInternational journal of molecular sciences2021

Investigation of NPB Analogs That Target Phosphorylation of BAD-Ser99 in Human Mammary Carcinoma Cells.

Swamy Savvemala Girimanchanaika, Dukanya Dukanya, Ananda Swamynayaka, Divya Maldepalli Govindachar, Mahendra Madegowda, Ganga Periyasamy, Kanchugarakoppal Subbegowda Rangappa, Vijay Pandey, Peter E Lobie, Basappa Basappa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Swamy Savvemala GirimanchanaikaLaboratory Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Manasagangotri, Mysore 570006, India.ORCID 0000-0003-0260-2737
Dukanya DukanyaLaboratory Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Manasagangotri, Mysore 570006, India.
Ananda SwamynayakaDepartment of Studies in Physics, University of Mysore, Manasagangotri, Mysore 570006, India.
Divya Maldepalli GovindacharDepartment of Chemistry, Bangalore University, Bangalore 560056, India.
Mahendra MadegowdaDepartment of Studies in Physics, University of Mysore, Manasagangotri, Mysore 570006, India.
Ganga PeriyasamyDepartment of Chemistry, Bangalore University, Bangalore 560056, India.
Kanchugarakoppal Subbegowda RangappaInstitution of Excellence, University of Mysore, Manasagangotri, Mysore 570006, India.
Vijay PandeyTsinghua Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
Peter E LobieTsinghua Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
Basappa BasappaLaboratory Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Manasagangotri, Mysore 570006, India.ORCID 0000-0002-8844-468X
University of Mysore · INBangalore University · INShenzhen Bay Laboratory · CNTsinghua–Berkeley Shenzhen Institute · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The design and development of a small molecule named NPB [3-{(4(2,3-dichlorophenyl)piperazin-1-yl}{2-hydroxyphenyl)methyl}-N-cyclopentylbenzamide], which specifically inhibited the phosphorylation of BAD at Ser99 in human carcinoma cells has been previously reported. Herein, the synthesis, characterization, and effect on cancer cell viability of NPB analogs, and the single-crystal X-ray crystallographic studies of an example compound (4r), which was grown via slow-solvent evaporation technique is reported. Screening for loss of viability in mammary carcinoma cells revealed that compounds such as 2[(4(2,3-dichlorophenyl)piperazin-1-yl][naphthalen-1-yl]methyl)phenol (4e), 5[(4(2,3-dichlorophenyl)piperazin-1-yl][2-hydroxyphenyl)methyl)uran-2-carbaldehyde (4f), 3[(2-hydroxyphenyl][4(p-tolyl)piperazin-1-yl)methyl)benzaldehyde (4i), and NPB inhibited the viability of MCF-7 cells with IC

Indexed as

bcl-Associated Death ProteinBreast NeoplasmsCrystallography, X-RayDensity Functional TheoryFemaleHumansMCF-7 CellsMolecular ConformationNitrobenzenesPhosphorylationSerine4-nitrophenethyl bromideBAD protein, humanbcl-Associated Death ProteinNitrobenzenesSerineBAD phosphorylationdrug designhuman mammary carcinomalead optimizationPetasis reaction

Identifiers

PMID34681659
PMCPMC8540132
OpenAlexW3206002514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.